Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.11
NAS:MLAB's Cash-to-Debt is ranked lower than
93% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. NAS:MLAB: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: No Debt Max: No Debt
Current: 0.11
Equity-to-Asset 0.57
NAS:MLAB's Equity-to-Asset is ranked lower than
57% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. NAS:MLAB: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MLAB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.91 Max: 0.96
Current: 0.57
0.53
0.96
Interest Coverage N/A
NAS:MLAB's Interest Coverage is ranked higher than
72% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. NAS:MLAB: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:MLAB' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 6.06
Beneish M-Score: -2.32
WACC vs ROIC
3.53%
9.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.42
NAS:MLAB's Operating Margin % is ranked higher than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. NAS:MLAB: 17.42 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MLAB' s Operating Margin % Range Over the Past 10 Years
Min: 17.42  Med: 28.52 Max: 36.1
Current: 17.42
17.42
36.1
Net Margin % 11.94
NAS:MLAB's Net Margin % is ranked higher than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. NAS:MLAB: 11.94 )
Ranked among companies with meaningful Net Margin % only.
NAS:MLAB' s Net Margin % Range Over the Past 10 Years
Min: 11.94  Med: 18.13 Max: 23.57
Current: 11.94
11.94
23.57
ROE % 12.31
NAS:MLAB's ROE % is ranked higher than
67% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. NAS:MLAB: 12.31 )
Ranked among companies with meaningful ROE % only.
NAS:MLAB' s ROE % Range Over the Past 10 Years
Min: 12.26  Med: 16.85 Max: 20.74
Current: 12.31
12.26
20.74
ROA % 6.73
NAS:MLAB's ROA % is ranked higher than
70% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. NAS:MLAB: 6.73 )
Ranked among companies with meaningful ROA % only.
NAS:MLAB' s ROA % Range Over the Past 10 Years
Min: 6.73  Med: 14.55 Max: 19.25
Current: 6.73
6.73
19.25
ROC (Joel Greenblatt) % 50.04
NAS:MLAB's ROC (Joel Greenblatt) % is ranked higher than
84% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. NAS:MLAB: 50.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MLAB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 48.21  Med: 68.68 Max: 80.32
Current: 50.04
48.21
80.32
3-Year Revenue Growth Rate 18.60
NAS:MLAB's 3-Year Revenue Growth Rate is ranked higher than
88% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. NAS:MLAB: 18.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MLAB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.2  Med: 18.6 Max: 39.4
Current: 18.6
1.2
39.4
3-Year EBITDA Growth Rate 14.60
NAS:MLAB's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NAS:MLAB: 14.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MLAB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.6 Max: 96.4
Current: 14.6
0
96.4
3-Year EPS without NRI Growth Rate 5.30
NAS:MLAB's 3-Year EPS without NRI Growth Rate is ranked higher than
58% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. NAS:MLAB: 5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MLAB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 4.7  Med: 12.1 Max: 171.4
Current: 5.3
4.7
171.4
GuruFocus has detected 9 Warning Signs with Mesa Laboratories Inc $NAS:MLAB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MLAB's 30-Y Financials

Financials (Next Earnings Date: 2017-07-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MLAB Guru Trades in Q2 2016

Chuck Royce 54,000 sh (-8.63%)
Jim Simons 101,600 sh (-25.51%)
» More
Q3 2016

MLAB Guru Trades in Q3 2016

Jim Simons 94,159 sh (-7.32%)
Chuck Royce 40,300 sh (-25.37%)
» More
Q4 2016

MLAB Guru Trades in Q4 2016

Chuck Royce 40,300 sh (unchged)
Jim Simons 83,300 sh (-11.53%)
» More
Q1 2017

MLAB Guru Trades in Q1 2017

Chuck Royce 50,072 sh (+24.25%)
Jim Simons 79,500 sh (-4.56%)
» More
» Details

Insider Trades

Latest Guru Trades with MLAB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334513    SIC: 3823
Compare:NAS:LMAT, NAS:ANGO, NAS:ATRS, NAS:PLSE, NAS:STAA, NAS:ELGX, NAS:ENTL, NAS:ATRC, NAS:UTMD, NAS:SIEN, NAS:LMNX, NAS:CFMS, NAS:IRTC, NAS:IVTY, AMEX:TRXC, NAS:LAKE, NAS:HBIO, AMEX:BVX, NAS:BIOL, NAS:EKSO » details
Headquarter Location:USA
Mesa Laboratories Inc designs, manufactures and markets quality control instruments and disposable products and also manufactures and markets biological indicators and distributes chemical indicators.

Mesa Laboratories Inc designs, manufactures and markets quality control instruments and disposable products and also manufactures and markets biological indicators and distributes chemical indicators. Its segments include Biological Indicators, Instruments, Cold Chain Monitoring and Cold Chain Packaging. The Biological Indicators division provides testing services, along with the manufacturing and marketing of biological indicators, instruments division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries, Cold Chain Monitoring develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure and Cold Chain Packaging Division provides packaging development consulting services and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.

Ratios

vs
industry
vs
history
PE Ratio 53.39
MLAB's PE Ratio is ranked lower than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. MLAB: 53.39 )
Ranked among companies with meaningful PE Ratio only.
MLAB' s PE Ratio Range Over the Past 10 Years
Min: 10.41  Med: 19.55 Max: 56.7
Current: 53.39
10.41
56.7
PE Ratio without NRI 53.39
MLAB's PE Ratio without NRI is ranked lower than
80% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. MLAB: 53.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
MLAB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.41  Med: 19.55 Max: 56.7
Current: 53.39
10.41
56.7
Price-to-Owner-Earnings 282.40
MLAB's Price-to-Owner-Earnings is ranked lower than
95% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. MLAB: 282.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MLAB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.53  Med: 19.86 Max: 300
Current: 282.4
12.53
300
PB Ratio 5.94
MLAB's PB Ratio is ranked lower than
71% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. MLAB: 5.94 )
Ranked among companies with meaningful PB Ratio only.
MLAB' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 3.36 Max: 6.29
Current: 5.94
1.78
6.29
PS Ratio 6.37
MLAB's PS Ratio is ranked lower than
71% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. MLAB: 6.37 )
Ranked among companies with meaningful PS Ratio only.
MLAB' s PS Ratio Range Over the Past 10 Years
Min: 2.32  Med: 3.98 Max: 6.86
Current: 6.37
2.32
6.86
Price-to-Operating-Cash-Flow 77.12
MLAB's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. MLAB: 77.12 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MLAB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.84  Med: 16.34 Max: 81.93
Current: 77.12
9.84
81.93
EV-to-EBIT 38.58
MLAB's EV-to-EBIT is ranked lower than
80% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. MLAB: 38.58 )
Ranked among companies with meaningful EV-to-EBIT only.
MLAB' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.3  Med: 13.1 Max: 42.2
Current: 38.58
5.3
42.2
EV-to-EBITDA 25.15
MLAB's EV-to-EBITDA is ranked lower than
68% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. MLAB: 25.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
MLAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 11.1 Max: 27.5
Current: 25.15
4.8
27.5
PEG Ratio 5.05
MLAB's PEG Ratio is ranked lower than
68% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. MLAB: 5.05 )
Ranked among companies with meaningful PEG Ratio only.
MLAB' s PEG Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.31 Max: 5.45
Current: 5.05
0.44
5.45
Shiller PE Ratio 66.64
MLAB's Shiller PE Ratio is ranked lower than
63% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. MLAB: 66.64 )
Ranked among companies with meaningful Shiller PE Ratio only.
MLAB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.04  Med: 31.6 Max: 70.82
Current: 66.64
16.04
70.82
Current Ratio 2.16
MLAB's Current Ratio is ranked lower than
60% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. MLAB: 2.16 )
Ranked among companies with meaningful Current Ratio only.
MLAB' s Current Ratio Range Over the Past 10 Years
Min: 1.55  Med: 8.9 Max: 18.4
Current: 2.16
1.55
18.4
Quick Ratio 1.32
MLAB's Quick Ratio is ranked lower than
65% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. MLAB: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
MLAB' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 6.21 Max: 14.6
Current: 1.32
0.97
14.6
Days Inventory 128.19
MLAB's Days Inventory is ranked higher than
50% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. MLAB: 128.19 )
Ranked among companies with meaningful Days Inventory only.
MLAB' s Days Inventory Range Over the Past 10 Years
Min: 104  Med: 131.52 Max: 201.41
Current: 128.19
104
201.41
Days Sales Outstanding 55.80
MLAB's Days Sales Outstanding is ranked higher than
59% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. MLAB: 55.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
MLAB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.8  Med: 66.32 Max: 75.09
Current: 55.8
55.8
75.09
Days Payable 19.57
MLAB's Days Payable is ranked lower than
93% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. MLAB: 19.57 )
Ranked among companies with meaningful Days Payable only.
MLAB' s Days Payable Range Over the Past 10 Years
Min: 9.42  Med: 19.82 Max: 35.03
Current: 19.57
9.42
35.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.42
MLAB's Dividend Yield % is ranked lower than
84% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. MLAB: 0.42 )
Ranked among companies with meaningful Dividend Yield % only.
MLAB' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 1.13 Max: 2.6
Current: 0.42
0.39
2.6
Dividend Payout Ratio 0.22
MLAB's Dividend Payout Ratio is ranked higher than
67% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. MLAB: 0.22 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MLAB' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.23 Max: 0.29
Current: 0.22
0.22
0.29
3-Year Dividend Growth Rate 3.30
MLAB's 3-Year Dividend Growth Rate is ranked lower than
68% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. MLAB: 3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MLAB' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 3.3
0
44.2
Forward Dividend Yield % 0.42
MLAB's Forward Dividend Yield % is ranked lower than
87% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. MLAB: 0.42 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.54
MLAB's 5-Year Yield-on-Cost % is ranked lower than
81% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. MLAB: 0.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MLAB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.5  Med: 1.46 Max: 3.37
Current: 0.54
0.5
3.37
3-Year Average Share Buyback Ratio -2.20
MLAB's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. MLAB: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MLAB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.5  Med: -0.5 Max: 6.5
Current: -2.2
-7.5
6.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.09
MLAB's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. MLAB: 3.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MLAB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.06 Max: 3.09
Current: 3.09
0.49
3.09
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.64
MLAB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
73% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. MLAB: 3.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.60
MLAB's Price-to-Median-PS-Value is ranked lower than
69% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. MLAB: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MLAB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 0.75 Max: 1.6
Current: 1.6
0.22
1.6
Price-to-Peter-Lynch-Fair-Value 5.13
MLAB's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.48 vs. MLAB: 5.13 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MLAB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.2 Max: 5.13
Current: 5.13
0.36
5.13
Earnings Yield (Greenblatt) % 2.59
MLAB's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. MLAB: 2.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MLAB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 7.7 Max: 18.7
Current: 2.59
2.4
18.7
Forward Rate of Return (Yacktman) % 11.78
MLAB's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. MLAB: 11.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MLAB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.5  Med: 19.55 Max: 30.3
Current: 11.78
11.5
30.3

More Statistics

Revenue (TTM) (Mil) $93.67
EPS (TTM) $ 2.91
Beta0.25
Short Percentage of Float6.68%
52-Week Range $102.14 - 169.81
Shares Outstanding (Mil)3.74
» More Articles for MLAB

Headlines

Articles On GuruFocus.com
Mesa Labs Reports Record Net Income and Adjusted Net Income Jun 07 2017 
Mesa Labs Declares Quarterly Dividend Apr 05 2017 
Van Den Berg Adds Four Stakes to Portfolio in Second Quarter Jul 14 2015 
Mesa Laboratories Inc. (MLAB) CFO, Secretary Steven W Peterson sells 10,000 Shares Mar 03 2011 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Nov 15 2010 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Aug 16 2010 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Feb 16 2010 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Nov 16 2009 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Aug 14 2009 
Mesa Laboratories Inc. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas Jul 20 2017
Align Technology Hits a 52-Week High on Solid Prospects Jul 18 2017
Medtronic InterStim System Shows Five-Year Positive Results Jul 18 2017
Haemonetics Plasma Arm Advances, Blood Center Sluggish Jul 17 2017
Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock? Jul 17 2017
BioTelemetry (BEAT) Acquires LifeWatch for $280 Million Jul 17 2017
Hill-Rom (HRC) at 52-Week High: What's Driving the Stock? Jul 17 2017
Avantor to Acquire VWR, Consolidation Promises Global Gains Jul 14 2017
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando Jul 14 2017
Abiomed (ABMD) Scores a Strong Buy Right Now: Here's How Jul 13 2017
Medtronic Enrolls First Patient Under STOP AF First Trial Jul 13 2017
Edwards Emerges Strong on FDA Nods, International Prospect Jul 12 2017
Here's Why You Should Add ResMed to Your Portfolio Now Jul 12 2017
CVS Health's MinuteClinic Joins EOHN for Workplace Healthcare Jul 12 2017
Express Scripts Rides High on Increased Generic Utilization Jul 12 2017
PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation Jul 12 2017
Mesa Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : MLAB-US : July 12,... Jul 12 2017
RTI Surgical at a 52-Week High: What's Driving the Stock? Jul 11 2017
Neogen Introduces Test for Listeria in Environmental Samples Jul 11 2017
FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach Jul 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}